Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Common Equity (2024 - 2025)

Historic Common Equity for Xilio Therapeutics (XLO) over the last 2 years, with Q3 2025 value amounting to -$8.1 million.

  • Xilio Therapeutics' Common Equity fell 13859.54% to -$8.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.1 million, marking a year-over-year decrease of 13859.54%. This contributed to the annual value of $17.6 million for FY2024, which is N/A changed from last year.
  • Per Xilio Therapeutics' latest filing, its Common Equity stood at -$8.1 million for Q3 2025, which was down 13859.54% from $7.1 million recorded in Q2 2025.
  • Xilio Therapeutics' Common Equity's 5-year high stood at $33.4 million during Q2 2024, with a 5-year trough of -$8.1 million in Q3 2025.